Presentation on Richter Group Report - 9 months to September 2021
November 08, 2021 at 04:58 am EST
Share
Richter Group
Report, M9 2021
Budapest, 8 November 2021
Report, M9 2021
Highlights I.
454,321 HUFm
Consolidated
sales+9.1%
20.7%
Operating margin
93,108 HUFm
Net profit*
+12.0%
* Net income attributable to owners of the parent.
55.5%
Gross margin
501 HUF
EPS
+12.1%
2
Report, M9 2021
Central Nervous System
Highlights II.
29 October 2021 - cariprazine
AbbVie announced top-line results from two Phase 3 clinical trials, evaluating the efficacy and safety of cariprazine (Vraylar®) as an adjunctive treatment for patients with major depressive disorder (MDD).
In one of the studies, cariprazine showed a statistically significant change to week six in the Montgomery- Åsberg Depression Rating Scale (MADRS) total score compared with placebo. In the other study, cariprazine demonstrated numerical improvement in depressive symptoms to week six in MADRS total score compared with placebo but did not meet its primary endpoint for either the 1.5 mg/day or 3.0 mg/day dose.
3
Report, M9 2021
Other
Corporate matters
11 August 2021 - Change in ownership structure
Richter informed its shareholders that according to the notice received from Hungarian National Asset Management Incorporated (hereinafter "HNMA Inc.") on 10 August 2021 in Gedeon Richter Plc. the influence (ownership ratio) of the Hungarian State represented by HNMA Inc. has decreased from 5.25% to 0%. Simultaneously the influence (ownership ratio) of Foundation for National Health and Education of Medical Doctors increased to 5.25%.
Domestic investors
9%
66%
International
Maecenas Universitatis
30 September 2021
investors
Corvini Foundation
10%
Mathias Corvinus
10%
Collegium Foundation
5%
Foundation for National
Health and Education of
Medical Doctors
4
Report, M9 2021
Reconciliation of consolidates sales by segments (HUFm)
HUFm
Increase
Decrease
Total
The pharma segment accounts for 80% of consolidated turnover.
The share of sales in Pharma segment declined within the Group.
Exchange rate loss at consolidated sales level: HUF 4,800m
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Gedeon Richter plc published this content on 08 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 November 2021 09:57:12 UTC.
Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Companyâs business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Companyâs core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Companyâs subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT. 
